STOCK TITAN
  1. Home
  2. News
  3. NDRA

ENDRA Life Sciences Inc - NDRA STOCK NEWS

Welcome to our dedicated news page for ENDRA Life Sciences (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on ENDRA Life Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ENDRA Life Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ENDRA Life Sciences's position in the market.

News
ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023
Rhea-AI Summary
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will host an offsite panel discussion at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The panel will focus on managing Metabolic-Associated Steatotic Liver Disease (MASLD) and feature three key opinion leaders in hepatology, endocrinology, and radiology. ENDRA will also showcase its TAEUS technology at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
conferences
-
News
Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023
Rhea-AI Summary
ENDRA Life Sciences announces acceptance of clinical abstract on Thermoacoustic assessment of fatty liver disease for presentation at Steatotic Liver Disease Summit 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
none
-
News
ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA
Rhea-AI Summary
ENDRA Life Sciences' De Novo request for the TAEUS liver system has advanced to substantive review with the FDA, potentially strengthening its competitive position in the non-invasive assessment of fatty liver tissue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.31%
Tags
none
News
ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents
Rhea-AI Summary
ENDRA Life Sciences announces the issuance of three new patents, bringing their global intellectual property portfolio to 67 issued patents. The patents strengthen the TAEUS system's proprietary position and provide protection for its novel hybrid ultrasound and thermoacoustic imaging technology. The patents cover a radio frequency applicator, a method and system for monitoring tissue temperature, and a method and system for determining fractional fat content of tissue. These patents advance and protect ENDRA's thermoacoustic imaging systems in areas with high unmet clinical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update
Rhea-AI Summary
ENDRA Life Sciences (NDRA) reported Q2 2023 financial results, submitted a De Novo Request to the FDA for the TAEUS liver system, showcased capabilities at European conferences, expanded its IP portfolio, and raised $4.7 million. Operating expenses decreased to $3.0 million, and net loss was $2.6 million. Cash and cash equivalents were $4.8 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.37%
Tags
earnings
-
News
ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA
Rhea-AI Summary
ENDRA Life Sciences has announced positive topline data from clinical studies comparing its Thermo Acoustic Enhanced UltraSound (TAEUS) system with MRI-PDFF. The data showed a sensitivity of 90% and a strong correlation coefficient of r=0.78 between TAEUS estimates and MRI-PDFF scores. The company has submitted a De Novo request to the FDA for the TAEUS system, which could potentially fulfill an unmet need for non-invasive assessment of fatty liver disease at a fraction of the cost of an MRI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.46%
Tags
none
News
ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
conferences earnings
-
News
ENDRA Life Sciences Announces Adjournment of 2023 Annual Meeting of Stockholders to July 25, 2023
Rhea-AI Summary
ENDRA Life Sciences Inc. has announced the adjournment of its 2023 Annual Meeting of Stockholders due to the lack of the required quorum. The meeting has been rescheduled for July 25, 2023, to allow more time for stockholders to vote on the proposals. Valid proxies previously submitted will be voted at the Adjourned Annual Meeting. Stockholders are encouraged to vote if they haven't done so yet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.83%
Tags
none
-
News
Study Highlighting ENDRA Life Sciences’ TAEUS Technology to be Presented at EASL International Liver Congress 2023
Rhea-AI Summary
ENDRA Life Sciences announces acceptance of poster presentation on Thermoacoustic assessment of fatty liver disease at International Liver Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
none
News
ENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
earnings
Stock NDRA logo
ENDRA Life Sciences Inc

Nasdaq:NDRA

NDRA Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NDRA Stock Data

4.08M
10.68M
3.15%
1.19%
0.28%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
United States
Ann Arbor

About NDRA

endra life sciences is bringing new capabilities to ultrasound. our photo-acoustic solutions help medical researchers screen and modify disease models with unparalleled quality and speed. we’re proud to have a global installed base of leading institutions using our nexus-128 system, the only 3d imaging solution for imaging anatomy, physiology and labeled molecular targets. the nexus 128 is a preclinical photoacoustic computed tomography (ct) scanner for small animal imaging. the system is used for simple, fast, non-invasive quantification of physiological parameters such as tumor vasculature without ionizing radiation. the fully-3d imaging technology used by the nexus 128 provides increased sensitivity compared to slice-based scanners, and dynamic (4-d) photoacoustic ct scans allow for applications such as quantification of probe uptake. the nexus 128 is currently being used by top imaging laboratories around the globe.